APA (7th ed.) Citation

Mohamed, M. F., Beck, D., Camp, H. S., & Othman, A. A. (2020). Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib. Journal of clinical pharmacology, 60(2), 188-197. https://doi.org/10.1002/jcph.1513

Chicago Style (17th ed.) Citation

Mohamed, Mohamed‐Eslam F., Denise Beck, Heidi S. Camp, and Ahmed A. Othman. "Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib." Journal of Clinical Pharmacology 60, no. 2 (2020): 188-197. https://doi.org/10.1002/jcph.1513.

MLA (9th ed.) Citation

Mohamed, Mohamed‐Eslam F., et al. "Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib." Journal of Clinical Pharmacology, vol. 60, no. 2, 2020, pp. 188-197, https://doi.org/10.1002/jcph.1513.